Source comparison
How Does PT-141 Work: Administration Method Comparison
Subcutaneous injection (abdomen/thigh) ~100% 60–90 minutes 12–24 hours Requires reconstitution with bacteriostatic water; injection site rotation needed to prevent lipohypertrophy Standard route. Optimal balance of onset, duration, and reliability Intranasal (
This comparison does not assign a generated winner or score.
- Subcutaneous injection (abdomen/thigh)
- ~100%
- 60–90 minutes
- 12–24 hours
- Requires reconstitution with bacteriostatic water; injection site rotation needed to prevent lipohypertrophy
- Standard route. Optimal balance of onset, duration, and reliability
- Intranasal (experimental)
- ~40–60%
- 30–45 minutes
- 8–12 hours
- Faster onset but lower bioavailability; mucosal irritation common; inconsistent absorption across individuals
- Not commercially available; absorption too variable for research use
- Oral (not viable)
- <5%
- N/A
- Degraded by gastric peptidases before reaching systemic circulation; no measurable effect
- Ineffective. Peptides require injection or mucosal routes
- Intravenous (research only)
- 100%
- 15–30 minutes
- Immediate onset but shortest duration; requires clinical setting; no advantage over subcutaneous for on-demand use
- Unnecessarily invasive for outpatient use; subcutaneous achieves equivalent bioavailability